Showing results (101-110 of 153) with videos related to

Sort By:
Pageof 16
Oncotarget|April 18, 2018
Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse eventsTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
Oncology Reports|October 30, 2020
CCL113, a novel sulfonamide, induces selective mitotic arrest and apoptosis in HeLa and HepG2 cellsRuirong Yi, Yoshifumi Ohno, Zheng Tian, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 14, 2024
Recent advances in hepatitis E virus research and the Japanese clinical practice guidelines for hepatitis E virus infectionTatsuo Kanda, Tian-Cheng Li, Masaharu Takahashi, et al.
International Journal of Molecular Sciences|April 26, 2017
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A InhibitorsTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
International Journal of Medical Sciences|April 21, 2020
Long-term administration of Tolvaptan to patients with decompensated cirrhosisKengo Kanayama, Tetsuhiro Chiba, Kazufumi Kobayashi, et al.
Liver Cancer|June 23, 2025
Comprehensive Analysis of Radiologic Cancer-Free Status through Various Treatment Approaches in Advanced-Stage Hepatocellular CarcinomaKeisuke Koroki, Sadahisa Ogasawara, Ryo Izai, et al.
Digestive Diseases and Sciences|May 24, 2011
Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2Tatsuo Kanda, Fumio Imazeki, Ryosaku Azemoto, et al.
Clinical and Molecular Hepatology|January 16, 2020
Switching to systemic therapy after locoregional treatment failure: Definition and best timingSadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, et al.
Oncotarget|March 17, 2018
Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitisTatsuo Kanda, Shin Yasui, Masato Nakamura, et al.
BMC Cancer|November 14, 2019
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinomaTakahiro Maeda, Hiroaki Kanzaki, Tetsuhiro Chiba, et al.
Pageof 16